| ARCHIMEDES DEVELOPMENT LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20120055929 | Child Resistant Container - A child resistant container ( | 03-08-2012 |
| 20120024724 | Medicine Disposal Container - Embodiments of the present invention provide a container for liquid medicine disposal, wherein the container has one or more interior surfaces associated with activated carbon cloth for capturing a drug dissolved in the liquid medicine. Embodiments of the present invention are particularly intended for use when dispensing a medicine spray, wherein the container must be held inverted whilst dispensing the spray. | 02-02-2012 |
| 20110182857 | Delivery of Drugs to Mucosal Surfaces - Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions. | 07-28-2011 |
| 20110104269 | COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS - An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis. | 05-05-2011 |
| 20100249170 | INTRANASAL COMPOSITIONS - A liquid aqueous formulation for the intranasal administration of apomorphine includes:
| 09-30-2010 |
| 20100203119 | PHARMACEUTICAL TREATMENT PROCESS USING CHITOSAN OR DERIVATIVE THEREOF - The present invention provides a solid composition for oral administration comprising:
| 08-12-2010 |
| 20100041624 | Buprenorphine formulations for intranasal delivery - Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C | 02-18-2010 |
| 20100021553 | PHARMACEUTICAL FORMULATIONS FOR INTRANASAL ADMINISTRATION OF PROTEIN COMPRISING A CHITOSAN OR A DERIVATIVE THEREOF - There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone. | 01-28-2010 |
| 20090130202 | Pharmaceutical Compositions - Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine. | 05-21-2009 |
| 20080248991 | Chitosan Containing Solution - The invention provides a composition comprising (i) chitosan, a salt or derivative thereof or a salt of a derivative thereof, (ii) a polyol-phosphate or sugar-phosphate salt, (iii) a plasticizer, and (iv) a therapeutic agent. Typically, the composition is a solution or suspension at ambient temperature but forms a gel at physiological temperatures. | 10-09-2008 |
